Cerebral ischemia/reperfusion (I/R) causes brain damage accompanied by ubiquitin accumulation and impairment of proteasome activity. In this study, we report that E2-25K, an E2-conjugating enzyme, is SUMOylated during oxidative stress and regulates cerebral I/R-induced damage. Knockdown of E2-25K expression protects against oxygen/glucose deprivation and reoxygenation (OGD/R)-induced neuronal cell death, whereas ectopic expression of E2-25K stimulates it. Compared with the control mice, cerebral infarction lesions and behavioral/neurological disorders are ameliorated in E2-25K knockout mice during middle cerebral artery occlusion and reperfusion. In particular, E2-25K is SUMOylated at Lys14 under oxidative stress, OGD/R and I/R to prompt cell death. Further, E2-25K downregulates the proteasome subunit S5a to impair proteasome complex and thus restrain proteasome activity under oxidative stress. This proteasome inhibitory activity of E2-25K is dependent on its SUMOylation. These results suggest that E2-25K has a crucial role in oxidative stress and cerebral I/R-induced damage through inhibiting proteasome via its SUMOylation.

Cell Death and Disease (2016) 7, e2573; doi:10.1038/cddis.2016.428; published online 29 December 2016

E2-25K SUMOylation inhibits proteasome for cell death during cerebral ischemia/reperfusion

Eun Il Jeong¹, Hae Won Chung¹, Won Jea Lee¹, Seo-Hyun Kim¹, Hyunjoo Kim¹, Seon-Guk Choi¹ and Yong-Keun Jung*¹

Stroke is a major cause of mortality and disability in humans. Because of the intricate pathological characteristics of ischemic neuronal cell death, diverse mechanisms and molecules associated with cerebral ischemia/reperfusion (I/R) have been reported. The mechanisms that are known to protect against I/R-induced neurotoxicity include: hypothermia,¹² autophagy (Tsc1),² autophagy° (Tsc1),⁴ preconditioning⁵,⁶ and activation of survival factors, such as HIF1,⁷,⁸ Nrf2,⁹ EPO,¹⁰ BDNF¹¹ and so on. In addition, cell death processes elicited by cerebral I/R include excitotoxicity (NMDAR),¹²,¹³ ion imbalance (Ca²⁺),¹⁴,¹⁵ inflammation¹⁶,¹⁷ and oxidative stress.¹⁸,¹⁹ Among them, an excess of reactive oxygen species (ROS) attributed to perturbation of mitochondrial metabolism, lipid peroxidation and inflammation response during I/R has a vital role in cell fate determination of the damaged neurons. Thus, understanding the ROS-mediated molecular events under I/R damage is important.

The ubiquitin–proteasome system is one of the main mechanisms for protein degradation. Short-lived or abnormal proteins are tagged by covalent modification of ubiquitin using E1, E2 and E3 enzymes.²⁰ Target proteins labeled with ubiquitin are then recognized by large protein complexes, proteasomes. When the number of damaged proteins is too large to be quickly removed, it leads to aggregation in pathological conditions. In addition, the impaired proteasome activity can also induce the accumulation of aggregation-prone proteins and damaged proteins. Evidence from a number of studies suggests that the proteasome might have an important role in I/R²¹,²² and cerebral I/R results in reduced proteasomal activity.²³ Besides, I/R is also involved in inimmediate production of various abnormal proteins due to oxidative stress and other mechanisms.²⁴ These proteins are reflected in the prolonged accumulation of polyubquitinated proteins that can be attributable to impaired proteasome activity that are observed in dying neurons but not in the remaining neurons that survive.²⁵ However, the mechanism of inhibition of proteasome activity in neurons after I/R remains unknown.

E2-25K (also known as HIP2) is an ubiquitin-conjugating enzyme and is ubiquitously expressed with the highest level of expression in the brain.²⁶ It is known to have a role in aggregate formation of expanded polyglutamine proteins and suppression of apoptosis in polyglutamine diseases, such as Huntington's disease.²⁷ In Alzheimer's disease, E2-25K acts as a mediator of Aβ neurotoxicity, which is also accompanied by coordinating endoplasmic reticulum (ER) stress and caspase-12 activity.²⁸,²⁹ Increasing evidence showed that E2-25K is also involved in the dislocation of newly synthesized MHC class I heavy chains from the ER,³⁰ formation of foam cells³¹ and proteolysis of Rb induced by E7 in growth-arrested cells,³² thus indicating the diverse roles of E2-25K in many pathways.

In the present study, we observed that E2-25K was SUMOylated under oxidative stress and I/R to mediate neuronal cell death and brain injury. In this process, SUMOylated E2-25K was crucial for regulating proteasome activity through S5a.

Results

E2-25K mediates neuronal cell death under oxidative stress. To characterize the role of E2-25K in I/R, we first examined the contribution of E2-25K to oxygen/glucose deprivation and reoxygenation (OGD/R)-induced neuronal cell death by targeting E2-25K expression with shRNA. We
confirmed that E2-25K expression was abolished in B103/sh-E2-25K cells (Supplementary Figure S1a). Incubation of B103 control cells in OGD/R apparently induced cell death after 44 h (Supplementary Figure S1b), resulting in 69% cell death at 48 h (Supplementary Figure S1c) and activation of caspase-3 (Supplementary Figure S1d). Compared with control cells, B103/sh-E2-25K cells were significantly resistant to OGD/R-induced cell death (Supplementary Figures S1c and d). Similar results were observed in experiments performed with primary cultured mouse cortical neurons. E2-25K knockout (KO) neurons were less vulnerable to cell death (20% versus 12% at 70 h) than the wild-type (WT) neurons under OGD/R (Figure 1a). Accordingly, caspase-3 activation was suppressed in E2-25K KO cortical neurons (Figure 1b). Although E2-25K KO mice were previously generated by the gene-trap method, E2-25K expression was not completely abolished in cortical neurons. Further, knockdown of E2-25K expression in SH-SYSY human neuroblastosoma cells also resulted in increased cell viability under OGD/R (Supplementary Figure S1e). Conversely, overexpressed E2-25K significantly increased OGD/R-induced cell death. Similar to OGD/R, E2-25K was also critical for cell death triggered by H2O2 (Supplementary Figures S1f and g). Together, these results suggest that E2-25K mediates neuronal cell death under OGD/R and oxidative stress.

E2-25K is SUMOylated only under oxidative stress. Interestingly, we observed that OGD/R induced higher molecular weight (38 kDa) of E2-25K, with in addition to its original form (24 kDa; Figures 1c and d). The appearance of 38 kDa E2-25K was proportional to the treated H2O2 concentration (100–300 μM; Figures 1e and h), whereas 24 kDa E2-25K was concomitantly reduced. As expected, 38 kDa E2-25K was abolished and 24 kDa E2-25K was rescued by treatment with the antioxidant NAC (Figure 1e; Supplementary Figure S1h). FACS analysis showed that exposure to either OGD/R or H2O2 (either 100 or 200 μM) generated similar levels of ROS in the cells (Supplementary Figure S1i).

Unlike in control cells, 38 kDa E2-25K was not detected in B103/sh-E2-25K cells even after exposure to H2O2 (Supplementary Figure S1j). In addition, 38 kDa E2-25K was proved as a SUMOylated form because it was also detected by anti-SUMO1 antibody (Figure 1e) and was reduced by knockdown of Ubc9, a SUMO-conjugating enzyme (Figure 1f). Further, immunoprecipitation (IP) analyses showed that GFP-fused E2-25K was SUMOylated in the transfected cells after exposure to H2O2 (Figure 1g). Unfortunately, there is no commercially available or no home-made antibody to perform IP assay for endogenous E2-25K. Therefore, we performed a semi-IP assay using GFP-fused E2-25K. All these results indicate that the 38 kDa band is SUMOylated E2-25K. Moreover, we found that such E2-25K SUMOylation occurred only under oxidative stress but not upon other toxic insults such as neurotoxic stress (Aβ), autophagy (serum deprivation), ER stress (thapsigargin) and apoptosis (etoposide) (Figure 1h).

E2-25K SUMOylation at Lys14 promotes cell death. To evaluate the importance of E2-25K SUMOylation in oxidative stress-induced cell death, we utilized an E2-25K K14R in which the Lys14 residue was replaced with Arg. The E2-25K Lys14 was previously reported as a major SUMOylation site using an in vitro system. As predicted, SUMOylation of E2-25K K14R was blocked under oxidative stress and that of activity-dead E2-25K C92S was partially inhibited (Figure 2a). Utilizing these E2-25K mutants, we then assessed the contribution of SUMOylated E2-25K to cell death. H2O2-mediated cell death was augmented by E2-25K WT and partially by E2-25K C92S, but not by SUMOylation-defective E2-25K K14R (Figure 2b; Supplementary Figure S2). Likewise, increased cell death was observed under OGD/R by the overexpression of E2-25K WT, but not by E2-25K K14R (Figure 2c). On the other hand, these distinct effects of E2-25K WT and K14R on cell death under oxidative stress were not observed in cell death triggered by other toxic signals, such as etoposide (Figure 2d) or thapsigargin (Figure 2e). We further confirmed that H2O2-induced E2-25K SUMOylation (Figure 2f) and cell death (Figure 2g) were increased by reconstituting E2-25K KO cortical neurons with E2-25K WT but not by E2-25K K14R. Therefore, E2-25K SUMOylation at Lys14 selectively promotes H2O2- or OGD/R-mediated cell death.

E2-25K deficiency improves MCAO/R injury-induced brain damage. To examine the pathophysiological significance of E2-25K function and modification, we performed middle cerebral artery occlusion for 30 min followed by reperfusion for 24 h (MCAO/R) in WT and E2-25K KO mice (Figure 3a). 2,3,5-Triphenyltetrazolium chloride (TTC) staining revealed that the cerebral infarction lesion was significantly ameliorated (about two-fold) in E2-25K KO mice compared with that in WT mice (Figure 3b). Accordingly, E2-25K KO mice showed lower neurological scores than WT mice (Figure 3c). As cerebral I/R causes impairment of sensory-motor deficit and a decline in hanging ability, we additionally performed the hanging wire grip test to evaluate grip strength and endurance. Compared with WT mice, E2-25K KO mice showed remarkably improved grip strength after MCAO/R (Figure 3d). All these results indicate that E2-25K exhibits a detrimental effect on both cerebral I/R injury and behavioral neurological disorders.

We then characterized E2-25K-mediated I/R damage in the mouse brains. As observed in in vitro OGD/R assay, we found that E2-25K SUMOylation occurred only in the ipsilateral hemispheres of WT mice, but not in the contralateral region (Figure 3e). In compliance with the ischemic damage, activated caspase-3 was observed in the ipsilateral hemispheres. We further divided the ipsilateral hemispheres after MCAO/R into three regions: core (the region most severely damaged by I/R), penumbra (a rim of the region surrounding the core), and region A (the remaining region unaffected by I/R). Western blot analysis revealed that E2-25K SUMOylation evidently occurred in the core region, paralleling caspase-3 activation (Figure 3f). These in vivo results imply the possibility that E2-25K SUMOylation occurs in the affected brain, probably to facilitate I/R-induced injury.

SUMOylated E2-25K impairs proteasome activity for cell death. Because E2-25K has the capability to inhibit proteasome activity and cerebral I/R decreases proteasome activity, we addressed whether E2-25K has a role in oxidative...
stress and I/R-mediated inhibition of proteasome activity. As expected, the accumulation of ubiquitin conjugates, an indicator of proteasome activity, and E2-25K SUMOylation were observed in SH-SYSY cells treated with H$_2$O$_2$ (Figure 4a) and B103 cells incubated under OGD/R (Figure 4b). On the other hand, these effects were alleviated by E2-25K deficiency (Figure 4b). In addition, measurement of proteasome activity using a fluorogenic peptide substrate revealed that the chymotrypsin-like activity was sharply reduced in control cells during the period of OGD/R, whereas it was less decreased in B103/sh-E2-25K cells (Figure 4c). In support of these facts, analysis of in vivo ischemic stroke revealed that activities of all
three enzymes (chymotrypsin-, trypsin- and caspase-like activities) of the proteasome were reduced in WT mice (Figure 4d). In contrast, these activities were not much impaired in E2-25K KO mice (Figure 4d). Thus, E2-25K functions to inhibit proteasome activity in cells and mouse brain during I/R. Moreover, treatment with low dose of MG132, a proteasome inhibitor, potentiated H$_2$O$_2$-mediated cell death (Supplementary Figure S3a), confirming that proteasome inhibition is accountable for oxidative stress-induced cell death.

To address whether E2-25K SUMOylation affected proteasome activity, we utilized the E2-25K K14R. As observed in E2-25K WT, proteasome activity was also inhibited by the
E2-25K deficiency ameliorates MCAO/R injury. (a) Schematic diagram showing the experimental schedule. (b) The 3–4-month-old male E2-25K WT and KO mice were subject to MCAO for 30 min and reperfusion for 24 h. The 2-mm coronal brain sections, which were prepared from the olfactory bulb to the cerebellum, were analyzed after TTC staining (n = 2 for each genotype in this figure; left). Bars represent the percentage of infarction area to whole area with mean ± S.E.M., WT mice, n = 6; KO mice, n = 8 for the analysis, unpaired two-tailed Student’s t-test, **P < 0.01 (right). (c) The neurological deficits in each mouse were assigned as a score (mean ± S.E.M., each sham, n = 5; WT mice, n = 19; KO mice, n = 22, two-way ANOVA followed by Bonferroni’s post hoc test, **P < 0.01). (d) The mice were analyzed with wire hanging test (mean ± S.E.M., each sham, n = 5; WT mice, n = 10; KO mice, n = 18, two-way ANOVA followed by Bonferroni’s post hoc test, *P < 0.05). (e) Brain extracts (except cerebellum) were prepared from non-ischemic (contralateral, C), ischemic (ipsilateral, I) and sham control (S) hemispheres of E2-25K WT and KO mice and analyzed by western blotting (upper). Bars indicate mean ± S.E.M. (lower; n = 4, two-way ANOVA followed by Bonferroni’s post hoc test, **P < 0.01, ***P < 0.001). (f) TTC-stained section showing examples of lesions from MCAO/R-treated WT mouse. Brain extracts were prepared from ischemic core, penumbra and the rest of the region (region A) in the ipsilateral region (upper) and analyzed by western blotting (lower). Asterisks indicate non-specific signals.
ectopic expression of E2-25K K14R in control cells (Figures 4e and f). On the contrary, E2-25K K14R rescued proteasome inhibition and the accumulation of ubiquitin conjugates under oxidative stress (Figures 4e and f). Confirming this, we found that proteasome activities were equally reduced in B103/sh-E2-25K cells that were reconstituted with E2-25K WT

Figure 4 E2-25K SUMOylation under I/R condition impairs proteasome activity. (a and b) SH-SY5Y cells were treated with 100 μM H2O2 for 12 h (a) and B103/con and B103/sh-E2-25K cells were exposed to OGD alone or followed by reoxygenation for the indicated times (b). Cell extracts were analyzed by western blotting. (c) B103/con and B103/sh-E2-25K cells were exposed to OGD for 3 h and reoxygenation for the indicated times. Cell lysates were analyzed for the proteasome activity using suc-LLVY-AMC. Values represent mean ± S.E.M. (n = 3, two-way ANOVA followed by Bonferroni’s post hoc test, *P < 0.05, **P < 0.01). (d) E2-25K WT and KO mice were perfused for 24 h after MCAO for 30 min. Tissue lysates (except cerebellum) from non-ischemic (contralateral, C) and ischemic (ipsilateral, I) hemispheres of mouse brains were examined for chymotrypsin-like (Suc-LLVY-AMC), caspase-like (Ac-GPLD-AMC) and trypsin-like (Bz-VGR-AMC) activities of the proteasome (mean ± S.E.M., sham WT and KO mice, n = 3; MCAO WT mice, n = 3; KO mice, n = 4, two-way ANOVA followed by Bonferroni’s post hoc test, *P < 0.05, **P < 0.01). (e and f) SH-SY5Y cells were transfected with pcDNA (pcd), E2-25K WT or K14R, treated with 100 μM H2O2 for 12–20 h and analyzed by western blotting (e) or examined for proteasome activity using suc-LLVY-AMC (f). Bars represent mean ± S.E.M. (n = 3, two-way ANOVA followed by Bonferroni’s post hoc test, ***P < 0.001)
or K14R under normoxia (Supplementary Figure S3b, upper), but were significantly rescued in B103/sh-E2-25K cells reconstituted with E2-25K K14R under oxidative stress (Supplementary Figure S3b, lower). Further, ubc9 knockdown restored E2-25K-mediated inhibition of proteasome activity to a level similar to the E2-25K K14R (Supplementary Figure S3c). Therefore, SUMOylated E2-25K functions to inhibit proteasome activity under oxidative stress.

Previous studies have shown that E2-25K synthesizes unanchored polyubiquitin chains without E3.\textsuperscript{36,37} Furthermore, accrual of unanchored polyubiquitin chains is probably repressor, as it functions as a competitive inhibitor of substrate binding to the proteasome and other ubiquitin receptors.\textsuperscript{34,38}

Therefore, we investigated whether SUMOylated E2-25K affected polyubiquitin chain synthesis \textit{in vitro}. There was no difference between E2-25K WT and K14R proteins in their activities to synthesize polyubiquitin chains (Supplementary Figure S3d). We again confirmed SUMOylation of E2-25K at Lys14 \textit{in vitro} (Supplementary Figure S3e) and utilized this form in an \textit{in vitro} ubiquitination assay. Compared with SUMOylation-defective E2-25K K14R, it seemed that SUMOylated E2-25K facilitated the formation of high-molecular-weight (HMW) ubiquitin chains (Supplementary Figure S3f). Collectively, SUMOylated E2-25K might prompt the formation of HMW ubiquitin chains under oxidative stress.

**SUMOylated E2-25K downregulates ubiquitin receptor S5a.** To address the mechanism by which SUMOylated E2-25K impairs proteasome activity, we evaluated the levels of proteasome subunits under oxidative stress. Among proteasome subunits and assembly chaperones, only S5a, an ubiquitin receptor within the proteasome,\textsuperscript{39,40} was significantly reduced by H\textsubscript{2}O\textsubscript{2} treatment in B103 cells but not in B103/sh-E2-25K cells (Figure 5a). S6a, another ubiquitin receptor within the proteasome,\textsuperscript{41} was not affected by H\textsubscript{2}O\textsubscript{2}. Similar results were observed in primary cortical neurons; S5a, but not S6a, was reduced in an E2-25K-dependent manner under oxidative stress (Figure 5b). Furthermore, S5a was greatly reduced in the ipsilateral hemispheres of WT mice during MCAO/R (Figure 5c). In contrast, the down-regulation of S5a was not observed in E2-25K KO mice. Thus, E2-25K is required for the downregulation of S5a during oxidative stress and MCAO/R.

We next examined the effect of E2-25K K14R on the regulation of S5a. Unlike E2-25K WT, ectopic expression of E2-25K K14R blocked the decline of S5a in H\textsubscript{2}O\textsubscript{2}-treated cells (Figure 5d). In normal condition, E2-25K WT and K14R had no different effects on S5a levels. Likewise, while S5a remained high in B103/sh-E2-25K cells even under oxidative stress, it was reduced in B103/sh-E2-25K cells reconstituted with E2-25K WT, but not with E2-25K K14R (Figure 5e). Accordingly, the accumulation of ubiquitin conjugates showed an inverse relationship with S5a levels. We found that this regulation of S5a had no relevance to its mRNA levels (Figure 5f). These results suggest that E2-25K SUMOylation is critical for the downregulation of S5a during oxidative stress.

We then assessed how S5a levels were altered by I/R injury. Western blotting showed that S5a was cleaved to generate a cleavage product with 36 kDa only in WT mice during OGD/R (Supplementary Figure S4a). This cleavage of S5a was evident in the core region and partial in the penumbra region but was not observed in the contralateral region (Supplementary Figure S4b). Moreover, the cleavage was proportional to E2-25K SUMOylation. As E2-25K does not have peptidase activity, S5a could be cleaved by another protease. Based on a previous report showing that S5a is cleaved by calpain during oxidative stress,\textsuperscript{42} we tested the effect of calpeptin, a calpain inhibitor, on S5a cleavage. As expected, S5a cleavage occurred in primary cortical neurons during oxidative stress, but was inhibited by the treatment with calpeptin (Supplementary Figure S4c). We also confirmed that intracellular Ca\textsuperscript{2+} level was upregulated in WT mouse cortical neurons, but less in E2-25K KO neurons, following H\textsubscript{2}O\textsubscript{2} treatment or under OGD/R (data not shown). Thus, it is likely that S5a is cleaved by calpain, which is activated by E2-25K during MCAO/R and H\textsubscript{2}O\textsubscript{2} treatment.

**Altered S5a disassembles the lid in the 19S and impairs the activity of 26S proteasomes.** S5a, which was identified as a subunit of the 19S regulatory particle of the 26S proteasome,\textsuperscript{39} is located at the interface between the lid and base of 19S.\textsuperscript{43,44} To address how the reduction of S5a impairs proteasome activity, we fractionated tissue extracts of the ipsilateral hemisphere with FPLC gel filtration analysis. Western blotting of the fractions showed that S5a in the 26S proteasome fractions (#9–17) and subparticle fractions (#25–29) was significantly reduced in WT ipsilateral hemisphere as compared with contralateral region, whereas other proteasome subunits, such as S7, β5, and 20S, were not altered (Figure 6a, left). In contrast, such reduction of S5a was not observed in E2-25K KO mice (Figure 6a, right). Interestingly, S10, one of the 19S lid subunits, was not altered in their total amount during oxidative stress (Figures 5a, c and e), but was reduced in the 26S proteasome fractions (#9–17) and shifted towards low-molecular-weight fractions (Figure 6a, left). Again, these changes of S10 were not observed in E2-25K KO mice (Figure 6a, right). Thus, reduced S5a in the 26S and 30S proteasome may cause disassembly of the lid in the 19S of the 26S proteasome.

We further examined the disassembly and activities of proteasome complexes with native gel analysis. The results revealed that a significant loss of enzyme activities in the 26S (RP-CP) and 30S (RP-2-CP) proteasomes was observed in WT mice but not in E2-25K KO mice (Figure 6b, top). Also, S5a levels were much less in the 26S (RP-CP) and 30S (RP-2-CP) proteasomes of the ischemic hemispheres in WT mice (0.34 and 0.77, compared with untreated control) than in E2-25K KO mice (1.37, compared with untreated control; Figure 6b). Like S5a, S10 levels were also decreased in the 26S and 30S proteasomes of WT ipsilateral hemisphere. Consistently, other subunits, such as S7 in the base of 19S and β5 in the 20S, were not altered in these complex. In addition, detailed analysis of every FPLC fractions confirmed drastic difference in the levels of S5a of the 19S (fractions #21–24) between the ischemic hemispheres of WT and E2-25K KO mice (Supplementary Figure S5). Collectively, these observations indicate that the level of S5a is downregulated by E2-25K under MCAO/R to alter the complex and activity of proteasomes, leading to proteasome impairment.
Discussion

Post-translational modification by SUMO is involved in various cellular processes and SUMOylated proteins in these processes can alter protein–protein interactions, subcellular localization and protein stability, or change their activities.45–47 In the present study, E2-25K SUMOylation occurs under OGD/R, but not by OGD alone, and by the pathophysiological concentrations of H$_2$O$_2$ (100–300 μM). As ROS produced under OGD/R is greater than that under OGD,48 it seems that ROS levels are critical for E2-25K SUMOylation. Interestingly, E2-25K was not SUMOylated in cells that were exposed to low doses (1 or 2 μM) of H$_2$O$_2$,49 as well as high doses of > 1 mM.
H$_2$O$_2$. Rather, E2-25K was induced without SUMOylation under those conditions (Supplementary Figure S1k) and functions to modify caspase-12. Thus, a certain level of intracellular ROS is required for E2-25K SUMOylation. Considering that E2-25K functions in diverse pathways, these results imply that E2-25K has multiple roles depending on its modification and expression level. In fact, ROS level has been measured in many diseases; it is ~160 $\mu$M in cerebral I/R injury and is upregulated by the A$\beta$ peptide by up to three-fold in Alzheimer’s disease.

The issue of whether inhibition of proteasome activity has a protective or detrimental role in stroke is controversial. With respect to the immunoproteasome, proteasome inhibitors are known to prevent ischemic damage. Although their mechanisms of action are unknown, proteasome inhibitors have been tested as neuroprotective drugs. On the other hand,
proteasome dysfunction causes protein aggregation and neuronal cell death after cerebral I/R.22,24,25,34 Even the immunoproteasome blocks protein aggregation and preserves protein homeostasis upon oxidative stress associated with inflammation.55,56 Our data are in line with the latter in that impaired proteasome activity is harmful in the context of I/R injury. In this case, an important question of how E2-25K impairs proteasome activity remains. E2-25K synthesizes unanchored polyubiquitin chains without E357–58 and proteasome activity can be hampered by them.34,38 In the same context, our analysis utilizing E2-25K K14R suggests that E2-25K SUMOylation stimulates the synthesis of polyubiquitin chains and restrains proteasome activity under oxidative stress. Nonetheless, E2-25K K14R still synthesizes polyubiquitin chains as much as E2-25K WT but much less than SUMOylated E2-25K, implying that the regulating E2-25K expression is also another way to synthesize polyubiquitin chains. A detailed characterization of the difference between these activities remains to be resolved. A previous report showed that E2-25K is SUMOylated at K14 in vitro and this SUMOylation interferes with the transfer of ubiquitin from the E1 enzyme to E2-25K.34 However, in our study, SUMOylated E2-25K was better at generating polyubiquitin chains than E2-25K K14R. Moreover, E2-25K was SUMOylated in vitro despite the presence of E1 (data not shown). This possibly occurs due to the presence of ubiquitin-charged E2-25K. In fact, there is no difference between ubiquitin-charged deSUMOylated and SUMOylated E2-25K in the ability to synthesize diubiquitin, that is, a facility of ubiquitin transfer.34 If E2-25K is able to accept activated ubiquitin from not only E1 but also from E2-25K through interaction with another ubiquitin-charged E2-25K as an ubiquitin donor,50 SUMOylated E2-25K may continue to generate polyubiquitin chains. Importantly, S5a was downregulated in affected neurons and tissues under oxidative stress and specifically reduced in the 26S and 30S proteasome complexes. Deletion of S5a results in difficulties in protein degradation.61,62 Thus, the lack of S5a in the proteasome causes accumulation of ubiquitin conjugates. Although previous reports have shown that oxidative stress leads to the separation of the 20S and 19S in neuronal cells,63,64 downregulation of S5a did not affect the dissociation 20S and 19S in the MCAO/R mice in our study. Recently, rpnl13, another polyubiquitin receptor in the proteasome, has also been reported to have a redundant role in the recognition of ubiquitinated proteins in a Drosophila.65 Unlike rpnl13, however, only S5a can connect the base and lid and stabilize them within 19S.66–68 Thus, according to our results showing the loss of S10 from proteasome following S5a reduction, impaired proteasome activity under oxidative stress is likely due to disassembly of the lid within 19S from 26S proteasome. Indeed, proteasome complex lacking the lid was observed in S5a-deficient cells.69,70 In this process, we speculate that the synthesis of polyubiquitin chains by SUMOylated E2-25K may form a positive-feedback loop to further impair proteasome activity. Eventually, the reason for the importance of impaired proteasomes in tissue damage remains to be assessed in the future.

In conclusion, our study suggests that E2-25K is an arbitrator of I/R-induced damage and its SUMOylation confers susceptibility to I/R by impairing proteasome activity, thus providing a potential therapeutic target in stroke.

Materials and Methods

Cell culture and DNA transfection. B103 and SH-SY5Y cells were maintained in Dubecoo’s modified Eagle medium (DMEM; Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine and penicillin/streptomycin. Primary neurons were prepared as described previously.28 In brief, the cortical neurons were cultured from embryonic day 14 and incubated in neurobasal media (GIBCO BRL, Carlsbad, CA, USA) containing B27 (Invitrogen). Transfection was carried out with polyethylenimine or LipofectAMINE reagent (Invitrogen) following the manufacturer’s instructions. For OGD/reoxygenation, cells were exposed to glucose-free DMEM within a hypoxic chamber (Billups-Rothenberg, Inc, San Diego, CA, USA, 1% O2). After OGD, the cells were reoxygenated under normoxic conditions in normal DMEM.

Antibodies. For western blotting, the following antibodies were used: anti-GFP, anti-tubulin, anti-Ub, anti-E2-25K, anti-synaptophysin antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-caspase-3, anti-S5a antibodies (Cell Signaling, Beverly, MA, USA); anti-SUMO1, anti-NEase antibodies (Zymed, Carlsbad, CA, USA); anti-S10 antibody (Genetex, Irvine, CA, USA); anti-S5a antibody (Novus, Littleton, CO, USA); anti-S5a, anti-S7, anti-PAC2, anti-f5, anti-20S core antibodies (Biomol, Farmingdale, NY, USA); anti-S2 antibody (Abcam, Cambridge, UK); anti-p27 antibody (Sigma-Aldrich, St. Louis, MO, USA); and anti-S5a antibody (Enzo, Plymouth Meeting, MA, USA). Anti-E2-25K antibody was described previously.28

Plasmid construction. The E2-25K and its active site mutant (C92S) have been described previously.28 E2-25K K14R was generated by PCR using primers containing the corresponding mutation (E2-25K[K14R]-5′-CGGGAATTCACGAGGCTGCTG-3′; E2-25K[K14R]-3′-5′-CACGACCTCTGCGAATCCCGC-3′), and confirmed by DNA sequencing analysis. To construct the E2-25K shRNA, heteroduplex oligomers containing sequences of human or rat E2-25K (E2-25K[shRNA#1]-5′-GGGAGTTCAAATTCAAGAGAATTGAACTCCCGCTTTGGAATCT-3′; E2-25K[shRNA#1]-3′-5′-AGTCTAGACACAGACAGTGCTCGTCCTGGAATTCTTCTCC-3′; E2-25K[shRNA#2]-5′-GGGAGTTCAAATTCAAGAGAATTGAACTCCCGCTTTTCTTTTTTA-3′; E2-25K[shRNA#2]-3′-5′-AGTCTAGACACAGACAGTGCTCGTCCTGGAATTCTTCTCC-3′; E2-25K[shRNA#3]-5′-GGGAGTTCAAATTCAAGAGAATTGAACTCCCGCTTTTCTTTTTTTA-3′; E2-25K[shRNA#3]-3′-5′-AGTCTAGACACAGACAGTGCTCGTCCTGGAATTCTTCTCC-3′; E2-25K[shRNA#2]-5′-GGGAGTTCAAATTCAAGAGAATTGAACTCCCGCTTTTCTTTTTTTTA-3′; E2-25K[shRNA#2]-3′-5′-AGTCTAGACACAGACAGTGCTCGTCCTGGAATTCTTCTCC-3′; E2-25K[shRNA#3]-5′-GGGAGTTCAAATTCAAGAGAATTGAACTCCCGCTTTTCTTTTTTTTA-3′; E2-25K[shRNA#3]-3′-5′-AGTCTAGACACAGACAGTGCTCGTCCTGGAATTCTTCTCC-3′). For construction of His-E2-25K, the E2-25K was cloned into pET28a using the primers (E2-25K-His6)-5′-ATGCTTAAAATTCTACCGGAGTTCAAATTCAAGAGAATTGAACTCCCGCTTTTCTTTTTTA-3′; E2-25K-His6)-3′-Xhol-5′-CGGGAATTCACGAGGCTGCGCCGCGCCGCGCGCGCT-3′; E2-25K-His6)-3′-Xhol; 5′-CGGGAATTCACGAGGCTGCGCCGCGCCGCGCGCT-3′).

Generation of stable cell line. B103 and SH-SY5Y cells were transfected with E2-25K or E2-25K shRNA using LipofectAMINE reagent for 24 h and then grown in selection medium containing 2 mg/ml of G418 (Invitrogen) for 2 weeks to generate stable E2-25K overexpression or knockdown cells. After single-cell cloning, the clones were screened by western blot analysis.

Viability test. Cell viability was measured using the propidium iodide. In the transient transfection experiments, cell viability was determined based on the morphology of GFP-positive cells under a fluorescence microscope (Olympus, Tokyo, Japan) and by trypan blue exclusion assays as described.28

E2-25K KO mice. Maintenance of and experimentation with E2-25K WT and KO mice on a BALB/c background28 were performed in accordance with the animal care guidelines of Seoul National University and the ARRIVE guidelines,71 including randomization, blinding, appropriate controls, inclusion and exclusion criteria, reporting of all animals used, and so on. All mice described for experiments in this study have been produced through intercross breeding between heterozygous E2-25K KO mice.

MCAO. The 3–4-month-old male E2-25K WT or KO mice were anesthetized with intraperitoneal injection of Zoletil/Rompun mix, and transient MCAO was performed as previously described.28 In brief, the right common carotid artery (CCA) was exposed through a midline incision in the neck and unilateral MCAO was performed by inserting a 6-0 silicone rubber-coated monofilament (Docoll Corp, Sharon, MA, USA). The suture was inserted into the CCA and proceeded to the internal carotid artery. The MCA was occluded for 30 min and then the suture was withdrawn to allow 24 h of reperfusion before sacrifice. In sham-operated mice, the carotid arteries were prepared surgically but the filament was not inserted. Then, the brain was collected and placed in a metallic brain matrix for tissue slicing (Daejong,
Native PAGE. Cell lysates were separated on 4% (w/v) native PAGE at 4 °C. The gel was overlaid with buffer containing Suc-LVLY-AMC, Bz-VGR-AMC and Ac-GPLD-AMC (Biolum) and a fluorometer (EnVision Multilabel Reader; PerkinElmer, Waltham, MA, USA) with excitation at 380 nm and emission at 460 nm.

Native PAGE. Native gel analysis was performed as previously described.26 Cell lysates were separated on 4% (w/v) native PAGE at 4 °C. The gel was overlaid with buffer containing Suc-LVLY-AMC and transferred to nitrocellulose membranes for western blot analysis.

Preparation of cell extracts and separation of proteasome complexes by gel filtration. Gel filtration was performed as previously described.26 In brief, brain extracts were filtered through a 0.2-μm membrane (Sartorius, Goettingen, Germany). Gel filtration was performed using a Superose 6 FPLC column (AKTA; GE Healthcare), and 0.25-m fractions were collected.26

Conflict of Interest
The authors declare no conflict of interest.

Acknowledgements. This work was supported by the Global Research Laboratory (NRF-2010-00341) and CRI grant (NRF-2013R1A1A1001686) funded by the Ministry of Education, Science and Technology.

1. Yenari MA, Han HS. Neuroprotective mechanisms of hypothermia in brain ischemia. Nat Rev Neurol 2012; 13: 267–278.
2. Wu TC, Grotta JC. Hypothermia for acute ischemic stroke. Lancet Neurol 2013; 12: 275–284.
3. Zhang X, Yan H, Yuan Y, Gao J, Shen Z, Cheng Y et al. Cerebral ischemia-reperfusion-induced autophagy protects against neuronal injury by mitochondrial clearance. Autophagy 2013; 9: 1321–1333.
4. Papadakis M, Hadley G, Xilouri M, Hoyte LC, Hoyte LS, Nagel S et al. Tsc1 (hamartin) confers neuroprotection against ischemia by inducing autophagy. Nat Med 2013; 19: 1561–1567.
5. Dnagui U, Becker K, Meisel A. Preconditioning and tolerance against cerebral ischemia: from experimental strategies to clinical use. Lancet Neurol 2008; 8: 398–412.
6. Gidday JM. Cerebral preconditioning and ischemic tolerance. Nat Rev Neurosci 2006; 7: 437–448.
7. Ballatore C, Miranda LF, Pichulik P, Dragstiljs I, Johnson RS, Chavez JC. Neuron-specific inactivation of the hypoxia inducible factor 1 alpha increases brain injury in a mouse model of transient focal cerebral ischemia. J Neurosci 2007; 27: 6320–6332.
8. Sharp FR, Bernaudin M. HIF1 and oxygen sensing in the brain. Nat Rev Neurosci 2004; 5: 437–448.
9. Hardinghe GM, Lipton SA. Regulation of neuronal oxidative and nitrosative stress by endogenous protective pathways and disease processes. Antioxid Redox Signal 2011; 14: 1421–1424.
10. Digicagiloylu M. Erythropoietin in stroke: quo vadis. Expert Opin Biol Ther 2010; 10: 937–949.
11. Kitagawa K. CREB and cAMP response-element-mediated gene expression in the ischemic brain. FEBS J 2007; 274: 3210–3217.
12. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 2006; 5: 165–170.
13. Li W, Xu X, Peng L, Zhang X, Zhang W. Soundarpandian MM et al. DAPK1 interaction with NMDA receptor NR2B subsite mediates brain damage in stroke. Cell 2010; 140: 222–234.
14. Gribov K, Starrett JE Jr, Dzovetski SJ, Hewawasam P, Boissard CG, Cook DA et al. Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat Med 2001; 7: 471–477.
15. Angel F, Verdeca P, Reboldi GP, Gattobigio R, Bentivoglio M, Staessen JA et al. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103, 793 subjects. Am J Hypertens 2004; 17: 817–822.
16. Isocoda C, Arratier J. The immunology of stroke: from mechanisms to translation. Nat Med 2011; 17: 896–908.
17. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol 2007; 184: 53–68.
18. McCann SK, Dusting GJ, Roulston CL. Early increase of Nox4 NADPH oxidase and superoxide generation following endothelin-1-induced stroke in conscious rats. J Neurosci 2006; 26: 2524–2534.
19. Rodriguez R, Fernández-Gajardo R, Gutiérrez R, Matamala JM, Carrasco R, Miranda-Marchak A et al. Oxidative stress and pathophysiology of ischemic stroke: novel therapeutic opportunities. CNS Neurol Drug Disc Targets 2013; 12: 698–714.
20. Ravid T, Hochstrasser M. Diversity of degradation signals in the ubiquitin-proteasome system. J Cell Biochem 2001; 80: 679–680.
21. Williams AJ, Hale SL, Moffert JR, Dave JR, Elliott PJ, Adams J et al. Delayed treatment with MLN519 reduces infarction and associated neurologic deficit caused by focal ischemic brain injury in rats via antiinflammatory mechanisms involving nuclear factor-kappaB activation, gliosis, and leukocyte infiltration. J Cereb Blood Flow Metab 2003; 23: 717–727.
22. Liu CL, Martone ME, Hu BR. Protein ubiquitination in postsynaptic densities after transient cerebral ischemia. J Cereb Blood Flow Metab 2004; 24: 1219–1225.
23. Keller JN, Huang FF, Zhu H, Yu J, Ho YS et al. Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat Med 2001; 7: 471–477.
24. Song S, Kim SY, Hong YM, Jo DG, Lee JY, Shim SM et al. Induction of ubiquitin-conjugating enzyme E2-25K in ischemic cell death. Cell Death and Disease 2013; 4: 1424–1436.
33. Pichter A, Knipscheer P, Oberhofer E, van Dijk WJ, Körner R, Olsen JV et al. SUMO modification of the ubiquitin-conjugating enzyme E2-25K. Nat Struct Mol Biol 2005; 12: 264–269.

34. Piotrowski J, Beal R, Hoffmann L, Wilkinson KD, Cohen RE, Pickart CM. Inhibition of the 26S proteasome by polyubiquitin chains synthesized to define detailed lengths. J Biol Chem 1997; 272: 29712–29721v.

35. Ko S, Kang GB, Song SM, Lee JG, Shin DY, Yun JH et al. Structural basis of E2-25K/UBB+1 interaction leading to proteasome inhibition and neurotoxicity. J Biol Chem 2010; 285: 36070–36080.

36. Chen Z, Pickart CM. A 25-kilodalton ubiquitin carrier protein (E2) catalyzes multi-ubiquitin chain formation by the 20S proteasome. J Biol Chem 1993; 268: 21835–21842.

37. Kalchiani MA, Graham RK, Xia G, Koide HB, Hodgson JG, Graham KC et al. Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J Biol Chem 1996; 271: 19385–19393.

38. Throver JS, Ustrell V, Pickart C, Rechsteiner M. Recognition of the polyubiquitin proteolytic signal. EMBO J 2000; 19: 84–102.

39. Deveraux Q, Ustrell V, Pickart C, Rechsteiner M. A 26S protease subunit that binds ubiquitin conjugates. J Biol Chem 1994; 269: 7059–7061.

40. Verma R, Oania R, Graumann J, Deshaies RJ. Multiubiquitin chain receptors define a layer of substrate selectivity in the ubiquitin-proteasome system. Cell 2004; 118: 89–110.

41. Lam YA, Lawson TG, Velayutham M, Zwenk JL, Pickart CM. A proteasomal ATPase subunit recognizes the polyubiquitin degradation signal. Nature 2002; 416: 763–767.

42. Huang Q, Wang H, Perry SW, Figueiredo-Pereira ME. Negative regulation of 26S proteasome stability via calpain-mediated cleavage of Rpn10 subunit upon mitochondrial dysfunction in neurons. J Biol Chem 2013; 288: 12161–12174.

43. Lander GC, Estrin E, Matyskiela ME, Bashore C, Nogales E, Martin A. Complete subunit architecture of the proteasome regulatory particle. Nature 2012; 482: 186–191.

44. Beck F, Unverdorben P, Bohn S, Schwitzae R, Pfeffer G, Sakata E et al. Near-atomic resolution structural model of the yeast 26S proteasome. Proc Natl Acad Sci USA 2012; 109: 14670–14675.

45. Johnson ES. Protein modification by SUMO. J Biol Chem 1994; 269: 7059–7061.

46. Verma R, Oania R, Graumann J, Deshaies RJ. Multiquitin chain receptors define a layer of substrate selectivity in the ubiquitin-proteasome system. Cell 2004; 118: 89–110.

47. Lam YA, Lawson TG, Velayutham M, Zwenk JL, Pickart CM. A proteasomal ATPase subunit recognizes the polyubiquitin degradation signal. Nature 2002; 416: 763–767.

48. Abramov AY, Scorziello A, Duchen MR. Three distinct mechanisms generate oxygen free radicals. Cell Death and Disease 2012; 3: 1947–1957.

49. Ide T, Takada K, Qiu JH, Saito N, Kawahara N, Asai A et al. E2-25K SUMOylation in ischemic cell death. J Biol Chem 2010; 285: 36080–36090.

50. Hyslop PA, Zhang Z, Pearson DV, Phebus LA. Measurement of striatal H2O2 by the cytotoxic potential of H2O2 in vitro. Proc Natl Acad Sci USA 2010; 107: 817–822.

51. Shim SM, Lee WJ, Kim Y, Chang JW, Song S, Jung YK. Role of S5b/PSMD5 in proteasome inhibition caused by TNF-α in neurodegeneration. Biochim Biophys Acta 2004; 1650: 517–523.

52. Thibodeaux H, Palmer JT, van Lookeren Campagne M, Van Bruggen N. Transient ischemia in the patency of the posterior communicating artery. J Cereb Blood Flow Metab 1998; 18: 1372–1380.

53. Zhang RL, Chopp M, Zhang ZG, Jiang Q, Ewing JR. A rat model of focal embolic cerebral ischemia. Brain Res 1997; 766: 83–92.

54. Gerlai R, Thibodeaux H, Palmer JT, van Lookeren Campagne M, Van Bruggen N. Transient focal cerebral ischemia induces sensorimotor deficits in mice. Behav Brain Res 2000; 108: 63–71.

55. Lee HJ, Pyo JO, Oh Y, Kim HJ, Hong SH, Jeon YJ et al. AK2 activates a novel apoptotic pathway through formation of a complex with FADD and caspase-10. Nat Cell Biol 2007; 9: 1303–1310.

56. Lee HJ, Pyo JO, Oh Y, Kim HJ, Hong SH, Jeon YJ et al. AK2 activates a novel apoptotic pathway through formation of a complex with FADD and caspase-10. Nat Cell Biol 2007; 9: 1303–1310.

57. Shim SM, Lee WJ, Kim Y, Chang JW, Song S, Jung YK. Role of S5b/PSMD5 in proteasome inhibition caused by TNF-α in neurodegeneration. Biochim Biophys Acta 2004; 1650: 517–523.

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

The Author(s) 2016